The law creates a pathway for the introduction and use of biosimilars into the mainstream marketplace. Biosimilar medications have the potential to provide safe and effective treatment to people with arthritis at a potentially lower cost than name-brand biologic medications.
Biologics are carefully engineered, and they can never truly be duplicated. This means that even biosimilars deemed interchangeable are not generic replicas of original biologics. Nationwide, states are now enacting legislation to create a pathway for biosimilars because current laws on generic substitution do not have jurisdiction on biosimilars.